Corporate Profile

A world where skin cancer no longer takes lives

Contact investor relations

Pioneers in melanoma detection, saving lives since 2005

50

+

accessible

Clinics in New Zealand

250K

trusted

Kiwis choose MoleMap

5m

+

experienced

Moles diagnosed

A world where skin cancer no longer takes lives

Our Mission

At MoleMap, our mission is simple yet profound: A world where skin cancer no longer takes lives. We are dedicated to eradicating skin cancer through early detection, advanced technology, and compassionate care, ensuring that no life is lost to this preventable disease.

Our Vision

We aspire to be Australasia's premier provider of skin cancer health care, specialising in surveillance, diagnosis, treatment, and recovery. Our commitment to excellence and innovation will set the standard in the industry and make a tangible difference in the lives of our patients.

Our History

2023

MoleMap reaches a milestone 100 clinics across ANZ

2022

MoleMap acquires SkinSpots and expands into skin cancer treatment

2021

MoleMap’s AI* division is founded in Kahu, NZ

2015

Artificial intelligence (AI) technology used to assist with skin cancer detection

2005

MoleMap expands to Australia

1996

MoleMap launches first ever melanographer / teledermatologist led skin screening program in New Zealand

Our Story

The Original Skin-Mapping System

Over 25 years ago, MoleMap's journey began with a groundbreaking idea. Our New Zealand founders recognised a critical gap in skin cancer detection. Routine skin checks were failing to identify many cases of melanoma, particularly at its early, treatable stages.

The technology and training available to doctors at the time were insufficient, leading to missed diagnoses and unnecessary procedures that caused both physical and emotional distress for patients.

A Spot of Kiwi Ingenuity

Determined to find a better solution, our founders created a unique skin-mapping system designed to track changes in the skin over time, offering a more accurate and early detection of melanoma. This innovative approach transformed skin cancer detection and has become a vital tool for patients and healthcare professionals.

Today, MoleMap operates over 100 clinics across New Zealand and Australia. Our system's accuracy has made it a cornerstone of melanoma research, contributing to advancements in the field, educating specialists and saving lives.

Leveraging AI for Enhanced Skin Checks

In 2018, we began developing our first AI product. By 2021, Kahu AI was created, dedicated to advancing research and development of AI in skin cancer detection. In 2024, Kahu AI became fully operational across all MoleMap New Zealand clinics.

Validated through the SMARTI study in collaboration with Melanoma and Skin Cancer Trials (MASC) and published in the Journal of the American Academy of Dermatology, Kahu AI has demonstrated an impressive 90% accuracy in detecting both melanoma and non-melanoma skin cancers. As we commence the TGA accreditation process in Australia, our journey from early adoption to leadership in AI-driven skin cancer detection shows our commitment to revolutionising healthcare.

* Kahu AI is only used in MoleMap New Zealand clinics and is not yet TGA-approved in Australia.

Our Team

Each member of our team has been hand-selected for their extensive expertise in the dermatology, healthcare and technology fields, able to drive growth initiatives with innovative solutions.

Executive Leadership Team

Michelle Aquilina has led major enterprise transformations, driven revenue growth into multimillion-dollar profits and revitalised brands into market leaders. Her commitment to enhancing patient experience has fostered patient-centred care and strong, transparent relationships with healthcare professionals. Michelle believes a holistic strategic approach and disciplined execution are crucial for achieving successful outcomes.

Michelle Aquilina

Chief Executive Officer

Mark Stokes brings 25 years of experience in business accounting and general management, ensuring the financial strength and stability of MoleMap. A Chartered Accountant since 2002, Mark has worked across New Zealand, Australia and the UK. He joined MoleMap in 2018, leading finance and operations through recent changes.

Mark Stokes

Chief Financial Officer

Jaime Schell, with over 15 years in sales and marketing, excels in M&A and creating win-win solutions for companies, partners and customers. She previously led a B2B marketing and sales agency, focusing on account-based strategies. As MoleMap's Chief Revenue Officer, Jaime is focused on driving the growth of our corporate wellness offerings.

Jaime Schell

Chief Revenue Officer

Johan Vendrig has extensive experience in health IT and is dedicated to leveraging technology for health businesses. Before joining MoleMap three years ago, he served as CIO at Auckland District Health Board, GM IT at Health Alliance and CIO at Orion Health.

Johan Vendrig

Chief Information Officer

Dr. Franz Strydom founded Skinspots to address the need for comprehensive skin cancer screening and treatment. He helped develop a skin cancer project for the Bay of Plenty Ministry of Health and is credentialed by the DHB and PHO for advanced skin cancer care. An accomplished speaker and educator, Dr. Strydom is the first New Zealand doctor to receive a fellowship from the Skin Cancer Association of Australia and New Zealand. He plays a key role in MoleMap’s growth strategy.

Dr. Franz Strydom

Chief Medical Officer, NZ Skinspots

Board of Directors

Jodi Mitchell brings 30 years of career experience in Health and Technology in both Governance and Executive roles. She joined the Board in 2019 and is the Chair of both MoleMap and Kahu. Now, as a full-time Professional Director, she is Board Trustee of Health Navigator Charitable Trust, Board Director of PreKure and Flux Federation and was a Director of the Digital Health Association of NZ for 10 years, which she chaired for the last five years on this tenure.

Jodi has also been the CEO of SimplHealth, a leading NZ Technology organisation providing national solutions in Child Health, Immunisation, and Disability Services, and implemented the Electronic Prescription Services across both NZ and Australia.

Jodi Mitchell

Chair

Kelvin Hyland has been a MoleMap Director since 2018. He is the Managing Director of Ossis Corporation (a Zimmer Biomet Group Company), which engineers and manufactures 3D orthopaedic implants. Previously, he was GM of EBOS Group’s Australasian medical device sector. Kelvin brings over 25 years of experience in the med tech sector with deep sales, operational and leadership experience from a $7b listed company.

Kelvin Hyland

Board Member

Liesl MacDonald is an Executive Director for MoleMap and brings 15 years of experience in acquisitions, value creation, investment management and finance to assist in the execution of MoleMap’s strategic projects. Liesl is a Strategic Projects Partner for Pioneer Capital where she was Investment Manager leading its investment initiative into MoleMap in 2018.

Liesl MacDonald

Board Member

Tim Kelsey is a Director at MoleMap and CEO of Beamtree (ASX: BMT), a leader in health data analytics and clinical decision support. He previously served as Senior Vice President of Analytics International at HIMSS, driving global digital health initiatives. Tim has also led national digital health strategies in Australia as Chief Executive of the Australian Digital Health Agency and in England as NHS National Director for Patients and Information. In 2018, he co-founded and chaired the Global Digital Health Partnership. A former UK journalist, Tim has dedicated his career to advancing digital health and care.

Tim Kelsey

Board Member

Dr. Amandeep Hansra is a leader in digital health with 17 years of clinical experience. She co-founded Caligo Health, offering consulting to government, hospitals and businesses, and has been a Clinical Reference Lead at the Australian Digital Health Agency for four years. Before joining MoleMap's board in 2021, Amandeep was CEO and Medical Director of Telstra's ReadyCare telemedicine joint venture. She is passionate about health tech startups and has been recognised with the Women Leading in Business Scholarship and Telstra Health’s 2021 Brilliant Women in Digital Health award.

Dr. Amandeep Hansra

Board Member

Ben Flay joined the MoleMap Board in February 2023, bringing expertise in investment management and corporate finance. He is currently an Investment Director at Pioneer Capital, having previously held a similar role at Marwyn Capital in London. Ben is a Chartered Accountant and a CFA Charterholder.

Ben Flay

Board Member

Annual Reports

We are committed to transparency and accountability. Our annual reports detail our achievements, financial health and strategic initiatives, reflecting our ongoing commitment to excellence in skin cancer care.

Annual Report 2022 Annual Report 2023 Annual Report 2024

Contact investor relations

Thank you! Your submission has been received!

Oops! Something went wrong while submitting the form.

Thanks for subscribing!

Keep an eye on your inbox. We'll be there soon with all the skinformation to help you stay safe.

Close

Oops! Something went wrong while submitting the form.

A world where skin cancer no longer takes lives

Pioneers in melanoma detection, saving lives since 2005

Our History

2023

2022

2021

2015

2005

1996

Our Story

The Original Skin-Mapping System

A Spot of Kiwi Ingenuity

Leveraging AI for Enhanced Skin Checks

Our Team

Executive Leadership Team

Board of Directors

Annual Reports

Contact investor relations

Subscribe to our monthly newsletter